Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study
- 428 Downloads
Drug repositioning strategies were employed to explore new therapeutic indications for existing drugs that may exhibit dual negative mGluR1/5 modulating activities as potential treatments for neuropathic pain.
A customized in silico-in vitro-in vivo drug repositioning scheme was assembled and implemented to search available drug libraries for compounds with dual mGluR1/5 antagonistic activities, that were then evaluated using in vitro functional assays and, for validated hits, in an established animal model for neuropathic pain.
Tizoxanide, the primary active metabolite of the FDA approved drug nitazoxanide, fit in silico pharmacophore models constructed for both mGluR1 and mGluR5. Subsequent calcium (Ca++) mobilization functional assays confirmed that tizoxanide exhibited appreciable antagonist activity for both mGluR1 and mGluR5 (IC50 = 1.8 μM and 1.2 μM, respectively). The in vivo efficacy of nitazoxanide administered by intraperitoneal injection was demonstrated in a rat model for neuropathic pain.
The major aim of the present study was to demonstrate the utility of an in silico-in vitro-in vivo drug repositioning protocol to facilitate the repurposing of approved drugs for new therapeutic indications. As an example, this particular investigation successfully identified nitazoxanide and its metabolite tizoxanide as dual mGluR1/5 negative modulators. A key finding is the vital importance for drug screening libraries to include the structures of drug active metabolites, such as those emanating from prodrugs which are estimated to represent 5–7% of marketed drugs.
KEY WORDSgroup I metabotropic glutamate receptor (mGluR) in silico drug repositioning mGluR1 mGluR5 nitazoxanide
Comprehensive clinical drug library
Central nervous system
G-protein coupled receptor
Metabotropic glutamate receptor
Molecular Operating Environment
Virtual clinical drug library
ACKNOWLEDGMENTS AND DISCLOSURES
The authors acknowledge the resources, encouragement and support provided by Snowdon, Inc. (Monmouth Junction, NJ, USA). WJW wishes to acknowledge partial support for this work from NIH-NIEHS P30 ES005022.
- 1.Center for Drug Evaluation and Research and FDA Basics. Is it true FDA is approving fewer new drugs lately? www.fda.gov/AboutFDA/Transparency/Basics/ucm247348.htm.
- 7.Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2014;0. doi: 10.1038/onc.2014.72
- 21.D’Antoni S, Spatuzza M, Bonaccorso CM, Musumeci SA, Ciranna L, Nicoletti F, et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev. 2014.Google Scholar
- 26.Kulkarni SS, Zou MF, Cao J, Deschamps JR, Rodriguez AL, Conn PJ, et al. Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists. J Med Chem. 2009;52:3563–75.PubMedCentralPubMedCrossRefGoogle Scholar
- 27.Lindsley CW, Bates BS, Menon UN, Jadhav SB, Kane AS, Jones CK, et al. (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem Neurosci. 2011;2:471–82.PubMedCentralPubMedCrossRefGoogle Scholar